New drugs and treatment targets in psoriasis.

In recent years, the increased understanding of the pathophysiology of psoriasis has resulted in several new treatments. The success of ustekinumab proved the importance of the IL-23/T helper cell 17 axis in psoriatic diseases. Several new biologics targeting this axis will reach the clinic in the next years. Biologics are costly, require injections, and some patients experience tacaphylaxis, thus, the development of orally available, small-molecule inhibitors is desirable. Among small-molecules under investigation are A3 adenosine receptor agonists, Janus kinase inhibitors, and phosphodiesterase inhibitors. We review published clinical trials, and conference abstracts presented during the last years, concerned with new drugs under development for the treatment of psoriasis. In conclusion, our psoriasis armamentarium will be filled with several new effective therapeutic options the coming years. We need to be aware of the limitations of drug safety data when selecting new novel treatments. Monitoring and clinical registries are still important tools.

• Publication year

  2015

• Venue

  Acta Dermato-Venereologica

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2340/00015555-1931PMID 25111317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-17 targeted therapies for psoriasis

  2013cited by this paper
• A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

  2013cited by this paper
• STAT1 expression and activation is increased in lesional psoriatic skin

  2013cited by this paper
• Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

  2013cited by this paper
• New therapies under development for psoriasis treatment

  2013cited by this paper
• Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up

  2013cited by this paper
• Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

  2013cited by this paper
• Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

  2012cited by this paper
• Targeting IL-17 and TH17 cells in chronic inflammation

  2012cited by this paper
• Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension

  2012cited by this paper
• Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

  2012cited by this paper
• Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

  2012cited by this paper
• Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

  2012cited by this paper
• Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

  2012cited by this paper
• Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

  2012cited by this paper
• Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

  2012cited by this paper
• Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study

  2012cited by this paper
• IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

  2012cited by this paper
• Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

  2012cited by this paper
• A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

  2011cited by this paper
• Erratum: TH 17 cells in tumour immunity and immunotherapy (Nature Reviews Immunology (2010) 10 (248-256))

  2011cited by this paper
• Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

  2011cited by this paper
• Advances in the treatment of moderate-to-severe plaque psoriasis.

  2011cited by this paper
• The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation

  2011cited by this paper
• Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

  2010cited by this paper
• Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

  2010cited by this paper
• TH17 cells in tumour immunity and immunotherapy

  2010cited by this paper
• Assessing long-term drug safety: lessons (re) learned from raptiva.

  2010cited by this paper
• Novel strategies for patients with chronic myeloproliferative disorders

  2009cited by this paper
• Targeting signaling pathways with small molecules to treat autoimmune disorders

  2008cited by this paper

• Role of LIGHT in the Inflammatory Mechanisms of Psoriasis via Upregulation of Proliferation and Cytokine Production of Keratinocytes

  2026cites this paper
• TGM1 as a novel signature gene in psoriasis identified by integrative bioinformatics and experimental validation

  2025cites this paper
• Biologics and small molecules for psoriasis: current and future progress

  2025cites this paper
• Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways

  2025cites this paper
• Terapias biológicas no manejo da psoríase

  2024influential citation
• Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective

  2024cites this paper
• LGR4 Deficiency Aggravates Skin Inflammation and Epidermal Hyperplasia in Imiquimod‐Induced Psoriasis

  2024cites this paper
• An observational study on treatment regimens and effectiveness for psoriasis in real-world settings among 407 patients in Southeast China

  2024cites this paper
• Current and emerging prospects in the psoriatic treatment.

  2023cites this paper
• Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions

  2023cites this paper
• Experiencia de un contrato de riesgo compartido basado en resultados para el tratamiento de psoriasis en placa con secukinumab (Cosentyx)

  2022cites this paper
• Successful treatment of secukinumab in severe plaque psoriasis

  2022cites this paper
• Calidad de vida, depresión y su relación con la severidad en la psoriasis

  2022cites this paper
• Secukinumab Therapy in Psoriasis Management

  2022cites this paper
• Hydrogel-mediated topical delivery of steroids can effectively alleviate psoriasis via attenuating the autoimmune responses.

  2022cites this paper
• Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline

  2021cites this paper
• Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status

  2021cites this paper
• Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges

  2020cites this paper
• New jak inhibitors for the treatment of psoriasis and psoriatic arthritis.

  2020cites this paper
• United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors

  2020cites this paper
• DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation

  2020influential citation
• Chalcones in Dermatology

  2020cites this paper
• 3D model of harlequin ichthyosis reveals inflammatory therapeutic targets

  2020cites this paper
• Développement de modèles tridimensionnels de peau immunocompétente : application au psoriasis, une dermatose inflammatoire chronique

  2019cites this paper
• Geraniol targets KV1.3 ion channel and exhibits anti-inflammatory activity in vitro and in vivo.

  2019cites this paper
• Protective effect of a topical sunscreen formulation fortified with melatonin against UV-induced photodermatitis: an immunomodulatory effect via NF-κB suppression

  2019cites this paper
• Association of total oxidant status, total antioxidant status, and malondialdehyde and catalase levels with psoriasis: a systematic review and meta-analysis

  2019cites this paper
• Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

  2019cites this paper
• Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon

  2018cites this paper
• Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo–in vivo evaluation study

  2018cites this paper
• MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles

  2018cites this paper
• Biological therapies in psoriasis - revisited

  2018cites this paper
• Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case–control study

  2017cites this paper
• Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis

  2017influential citation
• Purinergic Signalling: Therapeutic Developments

  2017cites this paper
• Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

  2017cites this paper
• Biologics in patients with skin diseases

  2017cites this paper
• Combination of MALDI-MSI and cassette dosing for evaluation of drug distribution in human skin explant

  2017cites this paper
• Biologic Agents In Systemic Dermatotherapy: Cutaneous And Systemic Side Effects.

  2017cites this paper
• Let-7a Inhibits T-Cell Proliferation and IFN-γ Secretion by Down-Regulating STAT3 Expression in Patients with Psoriasis

  2017cites this paper
• Apremilast for the management of moderate to severe plaque psoriasis

  2017cites this paper
• Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis

  2017cites this paper
• Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis.

  2017cites this paper
• A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast

  2016cites this paper
• 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009

  2016cites this paper
• Current status and future prospects for biologic treatments of psoriasis

  2016cites this paper
• Prokineticin 2 Plays a Pivotal Role in Psoriasis

  2016cites this paper
• Skin under Tnf influence: how regulatory T cells work against macrophages in psoriasis

  2016cites this paper
• Le psoriasis : physiopathologie, traitements et conseils à l’officine en 2016

  2016cites this paper
• Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis

  2016cites this paper
• Tofacitinib for the treatment of psoriasis

  2016cites this paper
• Novel topical treatments for psoriasis: of interest or irrelevant?

  2016cites this paper
• Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.

  2016cites this paper
• Systemic methotrexate for the treatment of psoriasis

  2015cites this paper
• Teil 1: neue gegen IL-17 und IL-23 gerichtete Therapien

  2015cites this paper
• Teil 2: kleinmolekulare Substanzen

  2015cites this paper
• Apremilast for the treatment of psoriasis

  2015cites this paper
• Tofacitinib for the treatment of moderate-to-severe psoriasis

  2015cites this paper
• Erythrodermic Psoriasis: Current and Future Role of Biologicals

  2015influential citation
• Update on psoriasis immunopathogenesis and targeted immunotherapy

  2015cites this paper
• Novel psoriasis therapies and patient outcomes, Part 3: Systemic medications.

  2015cites this paper
• The therapeutic potential of purinergic signalling.

  2010cites this paper